NewsBenzingaBarclays mantiene il giudizio “Overweight” su Charles River, alza il target di prezzo a 375 dollari Barclays mantiene il giudizio “Overweight” su Charles River, alza il target di prezzo a 375 dollari Benzinga 2026.11.05 18:17 (GMT+0) Open on Benzinga Other news UBS Maintains Buy on CDW, Raises Price Target to $195 UBS Maintains Buy on Addus HomeCare, Raises Price Target to $160 UBS Maintains Neutral on Qualcomm, Lowers Price Target to $180 UBS Maintains Neutral on HubSpot, Lowers Price Target to $240 UBS Maintains Buy on Edwards Lifesciences, Raises Price Target to $118 UBS Maintains Buy on Amplitude, Raises Price Target to $22